Efficacy and safety of currently marketed anti-osteoporosis medications

Reginster, Jean‐Yves; Neuprez, Audrey; Dardenne, Nadia; Beaudart, Charlotte; Emonts, Patrick; Bruyère, Olivier

doi:10.1016/j.beem.2014.09.003

Cited by 42 publications

(30 citation statements)

References 168 publications

(184 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Strontium ranelate is an agent currently employed in Europe for the treatment of severe osteoporosis in postmenopausal women, as well as in men [112]. It displays a dual mechanism of action, namely, bone forming and anti-resorptive properties, which lead to short-and long-term reduction in vertebral and non-vertebral fractures, such as hip fractures [84,113].…”

Section: Strontium Ranelate: Effects On Bonementioning

confidence: 99%

The calcium-sensing receptor in bone metabolism: from bench to bedside and back

et al. 2015

View full text Add to dashboard Cite

Calcium released in the bone microenvironment during remodeling is a major factor in regulating bone cells. Osteoblast and osteoclast proliferation, differentiation, and apoptosis are influenced by local extracellular calcium concentration. Thus, the calcium-sensing properties of skeletal cells can be exploited in order to modulate bone turnover and can explain the bone anabolic effects of agents developed and employed to revert osteoporosis.

show abstract

Section: Strontium Ranelate: Effects On Bonementioning

confidence: 99%

The calcium-sensing receptor in bone metabolism: from bench to bedside and back

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Oral administration of Strontium (Sr) ranelate has shown effectiveness in the prevention of both vertebral and non-vertebral osteoporotic fractures 11, 12 . Unlike other anti-osteoporotic agents widely used in clinical practice, such as bisphosphonates, estrogen, selective estrogen-receptor modulators (SERMs) and calcitonin, which inhibit bone resorption 9 , Sr ranelate also promotes bone formation 13–16 .…”

Section: Introductionmentioning

confidence: 99%

Injectable hybrid system for strontium local delivery promotes bone regeneration in a rat critical-sized defect model

Lourenço

Nevès

Ribeiro-Machado

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Strontium (Sr) has been described as having beneficial influence in bone strength and architecture. However, negative systemic effects have been reported on oral administration of Sr ranelate, leading to strict restrictions in clinical application. We hypothesized that local delivery of Sr improves osteogenesis without eliciting detrimental side effects. Therefore, the in vivo response to an injectable Sr-hybrid system composed of RGD-alginate hydrogel cross-linked in situ with Sr and reinforced with Sr-doped hydroxyapatite microspheres, was investigated. The system was injected in a critical-sized bone defect model and compared to a similar Sr-free material. Micro-CT results show a trend towards higher new bone formed in Sr-hybrid group and major histological differences were observed between groups. Higher cell invasion was detected at the center of the defect of Sr-hybrid group after 15 days with earlier bone formation. Higher material degradation with increase of collagen fibers and bone formation in the center of the defect after 60 days was observed as opposed to bone formation restricted to the periphery of the defect in the control. These histological findings support the evidence of an improved response with the Sr enriched material. Importantly, no alterations were observed in the Sr levels in systemic organs or serum.

show abstract

“…11-13 Our review found only four studies on the systemic repercussion of local Sr application. While one study reported increased levels of Sr in both urine and blood samples, 34 another showed similar urinary excretion of this element.…”

Section: Discussionmentioning

confidence: 99%

“…8-10 Nevertheless, the cardiovascular safety of oral Sr ranelate is still a matter of concern as a small but significant increase in non-fatal myocardial infarctions has been reported, 11-13 leading to strict indications and restrictions for its use. 11 …”

Section: Introductionmentioning

confidence: 99%

In vivo and clinical application of strontium-enriched biomaterials for bone regeneration

Nevès

Linhares

Costa

et al. 2017

Bone & Joint Research

View full text Add to dashboard Cite

ObjectivesThis systematic review aimed to assess the in vivo and clinical effect of strontium (Sr)-enriched biomaterials in bone formation and/or remodelling.MethodsA systematic search was performed in Pubmed, followed by a two-step selection process. We included in vivo original studies on Sr-containing biomaterials used for bone support or regeneration, comparing at least two groups that only differ in Sr addition in the experimental group.ResultsA total of 572 references were retrieved and 27 were included. Animal models were used in 26 articles, and one article described a human study. Osteoporotic models were included in 11 papers. All articles showed similar or increased effect of Sr in bone formation and/or regeneration, in both healthy and osteoporotic models. No study found a decreased effect. Adverse effects were assessed in 17 articles, 13 on local and four on systemic adverse effects. From these, only one reported a systemic impact from Sr addition. Data on gene and/or protein expression were available from seven studies.ConclusionsThis review showed the safety and effectiveness of Sr-enriched biomaterials for stimulating bone formation and remodelling in animal models. The effect seems to increase over time and is impacted by the concentration used. However, included studies present a wide range of study methods. Future work should focus on consistent models and guidelines when developing a future clinical application of this element.Cite this article: N. Neves, D. Linhares, G. Costa, C. C. Ribeiro, M. A. Barbosa. In vivo and clinical application of strontium-enriched biomaterials for bone regeneration: A systematic review. Bone Joint Res 2017;6:366–375. DOI: 10.1302/2046-3758.66.BJR-2016-0311.R1.

show abstract

Efficacy and safety of currently marketed anti-osteoporosis medications

Cited by 42 publications

References 168 publications

The calcium-sensing receptor in bone metabolism: from bench to bedside and back

The calcium-sensing receptor in bone metabolism: from bench to bedside and back

Injectable hybrid system for strontium local delivery promotes bone regeneration in a rat critical-sized defect model

In vivo and clinical application of strontium-enriched biomaterials for bone regeneration

Contact Info

Product

Resources

About